Two-stage deployment aneurysm embolization devices

- Covidien LP

Embolic implants, delivery systems and methods of manufacture and delivery are disclosed. The subject implants are deployed in two stages. If sized properly as observed in the first stage, they are deployed to the second stage and detached. If not sized properly in/at the first stage, the implants are designed to be withdrawn and replaced with a more appropriately sized implant or another treatment option selected. Some of the implant configurations may be withdrawn even after the second stage deployment as well.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
RELATED APPLICATIONS

This application is a continuation of International Patent Application No. PCT/US20121024747, filed on Feb. 10, 2012, entitled TWO-STAGE DEPLOYMENT ANEURYSM EMBOLIZATON DEVICES, which claims the benefit of and priority to U.S. Provisional Application No. 61/441,845, filed on Feb. 11, 2011, the entire contents of each being incorporated by reference herein.

BACKGROUND

Numerous companies have pursued ball-type embolization devices for aneurysm treatment. Many of these, including the Nfocus LUNA device and other embodiments disclosed in commonly-owned patent applications are designed to be sized to fit a given aneurysm when the implant is fully deployed outside a delivery catheter. The same is true for the braid-ball implants disclosed and produced by Sequent Medical, Inc.

At least with the LUNA device, if size as visualized upon deployment (under active x-ray—i.e., “medical imaging”) is acceptable to a physician, the implant is detached. If not, the device is retrieved and exchanged for a more appropriate size. No example of devices designed for intra-aneurysmal treatment are known in which confirmation of final sizing is accomplished under medical imaging where the implant is deployed only up to a pre-selected or identified point. Certainly, embolization coils are often partially deployed within an aneurysm and visualized to determine if their size and/or configuration is acceptable before further advancing the same and effecting release. However, these are not deployed to a specified point as marked on the delivery system for making a size check.

SUMMARY

Generally, braid-balls for aneurysm or other embolization through blood flow disruption and thrombus formation are described. More specifically, variations of the invention concern a subject hub region architecture that may be employed in a single-layer braid ball implant or a double-layer “LUNA” type (i.e., folded-over/flat) implant architecture.

In use, the bulb of the subject implant is deployed in an aneurysm with the estimated final position of the proximal end visualized by aligning a catheter marker with the device proximal end. The implant end may include a band or otherwise (such as by welding) serve as a hub to the braid from which the implant is constructed. Other options as described further below are disclosed as well.

Regardless, if the first stage/bulb “fits”, then the adjacent retracted hub region is fully deployed (i.e., the second stage is deployed) and the implant is released from its pusher. The position of the catheter shaft marker and shape of the (first) sizing stage of the implant may be selected from a number of options as shown and described, as well as others.

The shape in the hub region is preferably configured to provide force for self-actuation upon catheter exit. One advantageous configuration is substantially spherical. Another contemplated shape is defined by two conical bodies meeting around a common base. When inset in a more curvilinear (heart-shaped) in cross section, the deployed hub can provide additional blood flow satiation zone(s) within the implant.

In any case, the inset is provided such that it can retract even when the implant is compressed to fit a high aspect ratio aneurysm. As demonstrated, the implant is operable in a pocket simulating an aneurysm with a dome-to-width ratio of about 2:1. Based on the implant configuration, higher ratios will be possible as well.

The exemplary embodiment demonstrating such activity employs a small spherical inset region. The inset region was defined over a spherical ball about 3 mm in diameter, for an implant between at least about 6-7 mm in gross outside diameter. Thus, the nested inset region can fully expand even within the outer bulb when partially compressed. When using the double-cone shape for the inset region, the additional stored energy available at the medial crease can be of further assistance driving inset shape recovery. Moreover, the conical taper can provide improved clearance for full expansion of the inset form in cases where the outer body or bulb of the implant is further compressed.

The distal/terminal end of the implant and any associated proximal hub/band may be positioned at the periphery of the bulb of the implant when fully deployed, or more inset in varying degrees. When employed in a “LUNA” folded-flat configuration, the distal marker of the implant is internal and a tether extends to the proximal hub of the device. In a one-layer implementation (i.e., a configuration that presents one layer at the distal end of the implant with the option of more at a proximal side depending on inset shape configuration) the distal marker be provided by a radiopaque material (e.g., Pt) band capturing the braid. As to the proximal side of either such device, it may comprise a radiopaque band capturing the braid. As discussed in US Patent Application No. 2011/0319926 (Becking, et al.) another option is to remove the band after the braid has been glued to create a composite hub construct.

In yet another variation, no such hub or band is provided at the proximal end of the braid defining the implant. Instead, a length of braid (between about 1 and about 2 mm long) is employed as a delivery system interface. Such a “tail” or sleeve of braid, when confined within a catheter is able to firmly grip/interlock with a complementary delivery system surface. In such a system, the delivery system surface is also advantageously covered or constructed of braid of a similar wire size and configuration to promote interlocking. Once the implant is free of the catheter, the (formerly) confined sleeve of braid defining the implant tail opens to permit the inner delivery system pusher member to be pulled free.

The forming method for a LUNA-style hidden hub implant is detailed herein in two heatsetting stages. Stage 1 produces a double-layer “folded-flat” implant preform with a columnar inset. Stage 2 changes the shape of the inset into a spherical volume. In the second forming and heatsetting procedure, a proximal suture tie may be employed in defining a second folded-flat region like that at the distal side as formed in Stage 1. The second heatsetting cycle may also be employed to modify the shape of the outer bulb. For example, while retaining the “folded-flat” distal bend(s), the gross shape of the bulb may be compressed from a substantially cylindrical shape to a more squat or flattened “M&M” shape (e.g., ellipsoidal). So-shaped, greater radial force is available for aneurysm fit and/or a greater range of treatment sites made available. Further reference to heatsetting methodology and delivery systems as may be applied to the present invention are presented in U.S. patent application Ser. No. 12/465,475 and PCT/US2009/041313 and U.S. patent application Ser. No. 12/942,209 and PCT/US2010/56051, each incorporated by reference in its entirety.

Other manufacture techniques are applicable as well. For instance, a selective heat treatment approach is contemplated in which a portion of the implant performing being shaped is set over a ferromagnetic material (e.g., 304 magnetic stainless steel alloy) and is heated through induction utilizing a radio-frequency (RF) field. Such an approach strictly localizes the heat treatment to areas in contact with the induction-heated element. To insure that no other material is significantly heat-affected, such activity may be conducted under the flow of coolant such as Nitrogen or Argon gas or some other medium. In any case, such an approach may be advantageously used in the “Stage 2” operation described above for re-shaping the inset region, without applying a second heat treat to the remainder of the implant preform.

The body of the subject implants may be constructed of NiTi alloy that is superelastic at human body temperature. Advantageously, the wire is in the size range of 0.0008 to 0.0013 inches, although it may be larger or smaller. It may be etched pre- and/or post-heat treatment using AYA solution or by such processes employed by service providers including NDC, Inc. Binary Nitinol alloy may be employed, or the alloy may include Au, Pt, W, Ir, Pd, alloys thereof or another dense element to improve radiopacity. Another approach to improving radiopacity contemplates using a plurality of such wires or ribbons intermixed when braiding with Nitinol. Otherwise, Pt core Nitinol Drawn Filled Tube (DFT) may be employed or other means.

The braid matrix is particularly effective in promoting thrombosis in order to embolize an aneurysm as its density increases. For a given catheter crossing profile, a certain maximum braid configuration is possible. For example, “folded-flat” implants as further described herein that are intended to track to the neurovasculature through commercially available 3 Fr/0.027 inch catheters (such as the REBAR or MARKSMAN) may be constructed from a 72×0.001″ braid configuration (as originally provided or etched thereto) or 96×0.0009″ braid (ditto) configuration. In single layer implant architectures, 144-end braid configurations are feasible with similar crossing profile with wire size in the range of about 0.008 to about 0.0011 inches in diameter. Still, it is to be noted that higher end count braid (e.g., 192 or 288) can be employed in the subject invention as can other braid end multiples/configurations. Likewise, it is possible to construct braided implants indented for 0.021 inch catheter compatibility. These may advantageously use two layers of 48×0.001″ braid or higher “end” multiple counts in thinner wire/filament or single-layer 72 or 96 end braid selections, etc.

In any case, the subject inventions include the devices, kits in which they are included, methods of use and methods of manufacture. More detailed discussion is presented in connection with the figures below.

BRIEF DESCRIPTION OF THE FIGURES

The figures provided herein are not necessarily drawn to scale, with some components and features exaggerated for clarity. Variations of the invention from the embodiments pictured are contemplated. Accordingly, depiction of aspects and elements of the invention in the figures are not intended to limit the scope of the invention.

FIG. 1 illustrates a variation of the subject implant deployed in an side-wall aneurysm model;

FIGS. 2A and 2B and FIGS. 3A and 3B diagrammatically illustrate an implant in use with coordinated catheter systems at different first and second stages of implant deployment, respectively;

FIGS. 4A-4D illustrate the implant construction from FIG. 1 visualized through a clear catheter in the stages of deployment represented in FIGS. 2A-3B;

FIGS. 5A-5F illustrate inset configuration variations;

FIGS. 6A-6C illustrate deployment of an implant with a hubless delivery system interface employing yet another inset configuration;

FIGS. 7A-7D illustrate stages of implant production; and

FIG. 8 is a flowchart showing various implant manufacture options.

DETAILED DESCRIPTION

Various exemplary embodiments of the inventive aspects are described below. Reference is made to these examples in a non-limiting sense. They are provided to illustrate more broadly applicable aspects of the subject inventions. Various changes may be made to the subject matter described and equivalents may be substituted without departing from the true spirit and scope of the invention(s).

Aneurysm Embolization Systems

The embodiments described herein are specifically designed so that, when deployed to a given stage within an aneurysm, the size of this stage is representative of the final size and configuration of the implant upon final deployment with the delivery system. Several advantages can be achieved in conjunction with such a system. One such advantage involves the opportunity to minimize delivery profile and/or complexity given the unique implant/delivery system interaction enabled. Another advantage involves the opportunity to provide larger implant sizes for a given delivery profile. Still another set of advantages involves the ease of expanded implant recapture, together with associated procedural and patient safety advantages. All told, aspects of the present invention (alone and/or in combination with one another) provide for a new and useful system for neurovascular aneurysm treatment or for treating other vascular, pocket-type or luminal defects.

FIG. 1 shows an implant 10 delivered according to the subject methodology as deployed in an side-wall aneurysm model 2. The model includes a parent vessel 4 and aneurysm fundus 6 filled by the implant 10. The implant is delivered in association (preferably via a detachable association vs. simple abutment) with a pusher 20. The implant comprise an outer bulb 12 and a substantially spherical inset region 14. A dense and complex structure is thus presented to the direction of blood flow (as indicated by arrows) to help promote blood thrombosis via disruption of its flow. Markers are optionally present at proximal and distal extents 16, 18 of the implant.

FIGS. 2A and 2B and FIGS. 3A and 3B diagrammatically illustrate the implant in use with coordinated catheter systems. FIGS. 2A and 2B illustrate one optional approach to staged deployment; FIGS. 3A and 3B illustrate another. All of these figures illustrate a generic distal implant architecture 30 in which a distal marker 32 diagrammatically pictured. In each view, the implant includes a proximal hub/marker band 34 operating as an interface region to an (optionally detachable) pusher 40. The hub and pusher may be connected by a mechanical detachment interface as described in the above-referenced patent applications, an electrolytically-severable joint, a meltable polymer filament, etc. In any case, the pusher is shown within the end of a microcatheter 50. The microcatheter includes a distal marker 52 and a more proximal reference marker 54.

In FIG. 2A, the reference marker is set at a position such that when the implant proximal hub/marker 34 is aligned therewith the freed/expanded portion of the implant is deployed in a “teardrop” of approximately the same height of the finally deployed implant shape as shown in FIGS. 2B and 3B. Likewise, the catheter reference marker shown 54′ in FIG. 3A is positioned such that a “mushroom” shape with flats 36 is produced upon hub 34 alignment therewith. Again, this intermediate implant body shape is similarly sized to the finally delivered implant configuration.

As such, at either intermediate stage of delivery (i.e., in a system configured per FIG. 2A, 3A or related thereto) a physician can determine if the implant is the proper size selected for the aneurysm to be treated by visualizing the position of the distal marker 32 in/on the implant and the distal marker 52 of the catheter. If the distal marker of the catheter is positioned at the neck of the aneurysm when the implant is in the first/intermediate stage of delivery, then the physician is offered an indication (mid-procedure) that upon completion of implant deployment that the proximal surface of the implant will be likewise so-positioned, as desired. Thus, an aspect of the invention concerns a catheter with a marker system and an implant (or an implant pusher as further described below) that include radiopaque markers coordinated for a first “check” stage of deployment followed by a “final” release/released deployment stage.

FIGS. 4A-4D illustrate the implant construction in stages of deployment visualized within a glass vial serving a second model 2′. The implant 30 is shown at various positions confined within a clear sheath 50′ simulating a catheter. Proximal to a marker element 34 seen in each image is a coil-reinforced length 22 simulating a pusher. FIG. 4A illustrates the implant in a first stage of the deployment of bulbous portion with the catheter end at point A. In FIG. 4B, the full-size teardrop sizing-check shape has developed with the catheter end at point B. With little or no substantial change in height, the mushroom sizing shape is developed with the catheter end at point B′. As evident from movement of marker 34, however, the pusher has been advanced. Upon advancement of the pusher and marker 34 to its ultimate/final position before pusher detachment, the final implant shape is formed with no significant difference in the position of the proximal face of the implant as evident by the alignment of the lead-line arrows.

Notably, all of the figures up to this point illustrate an inset region 14 configuration as shown in cross section per FIG. 5A. Likewise, FIG. 5A illustrates the manner in which the sizing of the inset region 14 accommodates different compression factors 30, 30′ of the same implant ball or bulb. The relatively small(er) spherical inset configuration in FIG. 5A is advantageously formed as further described below. Moreover, it demonstrates robust recovery and actuation as pictured. However, other inset shapes or forms offer further advantages and options as described below.

For example, FIG. 5B illustrates an inset 60 that is “heart shaped” in cross section. Such an inset offers additional clearance for bulb compression along a conical proximal section 62. Yet, the curve 64 to the distal section facilitates recapture of the device even after complete exit of extension 66 and hub 34 from the delivery catheter. By way of contrast, a double-conical shaped inset 70 as shown in FIG. 5C may “lock” with the catheter at the deeply inset “V” junction 72. Yet, the double-cone shape may be desirable because the increased number of sharp bends or transitions within the profile can help drive predictable shape recovery and increase resistance to radial compression within the proximal portion of the device.

FIG. 5D illustrates a second species of conical inset 74. In this variation, the two cones are adjacent, each with its own base 76, 76′ instead one that is conjoined. Further, FIG. 5D illustrates the manner in which any “tail” or extension section of the braid connecting to the hub 34 can be made short or essentially eliminated as compared to the previous variations. Moreover, the upper and lower cones are set at different angles so as to close the proximal end of the device at 78. Naturally, the previous inset variations can receive similar treatment as well.

FIG. 5E illustrates an approach in which the entry/exit port of the hub 34′ is inverted. Thus, recapture into a catheter requires a 180 degree bend form at the braid/hub junction. It will track the same way in the catheter for deployment. Such a feature may limit catheter downsizing. However, this feature can be accommodated by utilizing finer wire (e.g., 0.0008 inch diameter or less) able to bend in a tighter radius than heavier wire.

Again, the length or position of the inset extension 82 can be varied. For example, it may be desirable to extend it such that the position of the hub marker 34′ appears in roughly the center of implant 30 when uncompressed as illustrated in dashed line. Such an approach may be desirable when intending to fill a cavity with multiple numbers (e.g., in a multi-ball treatment approach to giant aneurysm) of the same implant that are allowed to fully expand, rather than form-fitting a single implant to fill an aneurysm. In which case, the hub can serve as a single, centrally-located marker.

Next, FIG. 5E illustrates an inset 90 that includes no hub and/or marker arrangement. Instead, this inset is configured especially for use with a delivery system as illustrated in FIGS. 6A-6C. Its shape is set to open when uncompressed by a catheter at bulb 92, while offering additional compression force at bends 94 for delivery system securement (via increased linear pressure) when the shape is compressed within the delivery catheter.

With respect to FIGS. 6A-6C, these illustrate an implant 30 with a urn or vase-shaped inset 100 as shown deployed/developed in FIGS. 6B and 6C. Such an inset offers advantageous proximal-side clearance, with a flat top 102 reducing inset height, and a distal crease 104 storing energy upon compression to drive shape recovery upon catheter release.

More generally, FIG. 6A illustrates implant 30 with bulb 12 outside of a delivery catheter 50 and implant tail 106 (before it transforms into the inset shape 100) still located therein. An interface segment 108 of the tail surrounds a textured (optionally by matching braid) retention section 120 of a pusher 122.

The whole length of the pusher may comprise metal braid which is encased/co-extruded by Polyimide with the distal section ablated from the braid. Components for such construction and ablation services are available from Microlumen, Inc. Tapered flex can be designed into the shaft by further selective ablation and/or including a taper-ground wire (floating or bonded) within a lumen of the pusher construction.

The delivery microcatheter includes a distal soft tip 56 and distal marker 52. A proximal reference marker 54 on the catheter is shown located between a pair of reference markers 110 on pusher 122. So long as the catheter holds the implant interface section compressed to the pusher retention section, the implant can be retrieved.

However, upon full deployment as shown in FIG. 6B, the interlocking interface between the implant and pusher is lost. At this point, pusher 122 may be withdrawn as shown in FIG. 6C and the catheter withdrawn as well. As positioned, the distal end of the catheter continues to mark the proximal position of the implant as the pusher is withdrawn, with only a small gap.

Also noteworthy is manner in which the inset may be shaped to facilitate implant release. As illustrated by dashed line of features 102′ and 108′ in FIG. 6C, the inset may be shaped to specifically pull-away from the pusher retention section upon exit from the delivery microcatheter.

Implant Manufacture

As referenced above, the subject implant architecture may be employed in a single layer braid ball implant or a double-layer LUNA type (folded-over/flat) approach. FIGS. 7A-7D illustrate aspects of manufacture in the latter case. Further details may be appreciated in reference to the application Ser. Nos. 12/465,475 and 12/942,209 and PCT/US2009/041313 and PCT/US2010/56051, each of which is incorporated by reference in its entirety.

As illustrated in FIG. 7A, a “Stage 1” or “Intermediate” state implant preform 200 can be shaped and heatset in association with internal heatsetting tooling element or form 210 and such other elements as described in the referenced descriptions with the addition of a deep columnar inset 202 formed with sleeve 212. With a close-fit relation between the layers of braid 230, 232 and the form elements 210, 212 tight radius bends are set at the turns 224 as indicated.

Once freed of the form elements as shown in FIG. 7B, preform 202 is better visualized as including a generally bulbous portion 204 along with inset 202 and extension or tail region 206. The depth “ID” of the inset is coordinated to facilitate its acceptance of a secondary internal form 214 as shown in FIG. 7C. With a tie 216 to hold it in place, the extent of the bulb 204 (shown as inverted sections 204FIG. 7C) can be reversed or “flipped” back into shape as shown in FIG. 7D.

With a mandrel 218 secured (e.g., by a metal tie 220) in position relative to form 214, a shoulder 222 can be used to compress a proximal fold 234 in the device, and a table or flat 222 can be used to compress the bulb against table element 224 into a modified shape (in this case more “squat” or ellipsoidal in cross-section) in a second heatsetting step to define a “Stage 2” of “Final” shape preform 200′.

Such a process flow path is illustrated as the left path in the flowchart of FIG. 8. Specifically, after forming the native braid (previously heatset or not) from which the implant is constructed over and within mandrel/form pieces at 300, the body is heatset at 302. Freed from the first set of heatsetting fixtures, it is optionally reshaped/reformed at 304, followed by a second overall heatsetting procedure 306. Finally, at 308, further processing such as optionally hubbing with marker bands, installing other marker features, hub welding, etc. is performed and then loading onto any optional delivery system pusher, onto packaging and sterilization as is common.

As an alternate flow path, after the first heatsetting and second shaping, only the inset is heatset at 306′. This can be accomplished as described above using a ferromagnetic material and induction field to concentrate heat for setting the shape of the braid in contact with element 214, for example.

Generally when the braid comprises Nitinol, any such heatsetting is accomplished between 500-550° C. for a period up to about 5 minutes. Such heating may be followed by quenching in water or be otherwise performed.

Regardless, it is further contemplated that the entire shaping of the implant may occur in one more complex cycle 310 in which each of the bulb and inset portions of the implant are formed simultaneously over a more complex set of nested forms. Such an approach may be especially viable when the implant only comprises a single layer of braid instead of also including a folded-flat distal section.

Variations

The subject methods may include each of the physician activities associated with implant positioning and release. As such, methodology implicit to the positioning and deployment of an implant device forms part of the invention. Such methodology may include placing an implant within a brain aneurysm, or at parent vessel targeted for occlusion, or other applications. In some methods, the various acts of implant introduction to an aneurysm or parent vessel are considered. More particularly, a number of methods according to the present invention involve the manner in which the delivery system operates in reaching a treatment site, for example. Other methods concern the manner in which the system is prepared for delivering an implant.

Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there is a plurality of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said,” and “the” include plural references unless specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as the claims below. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

Without the use of such exclusive terminology, the term “comprising” in the claims shall allow for the inclusion of any additional element irrespective of whether a given number of elements are enumerated in the claim, or the addition of a feature could be regarded as transforming the nature of an element set forth in the claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.

The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of the claim language. All references cited are incorporated by reference in their entirety. Although the foregoing invention has been described in detail for purposes of clarity of understanding, it is contemplated that certain modifications may be practiced within the scope of the appended claims.

Claims

1. An aneurysm treatment system comprising:

a catheter with a distal marker and a proximal reference marker;
an implant pusher; and
an implant connected to a distal end of the implant pusher and comprising a bulbous portion and a tail portion, the tail portion adapted to be received in a linear configuration within the catheter with a distal end of the tail portion being proximal to the bulbous portion when the implant is in an intermediate stage, the tail portion defining an inset within the bulbous portion when the implant is in a final stage,
wherein at least one of the pusher and the implant comprises an implant marker, wherein when the implant marker is aligned with the proximal reference marker, the implant is in the intermediate stage with the bulbous portion of the implant deployed from the catheter, wherein, when the implant marker is aligned with the distal marker, the implant is in the final stage with the implant deployed from the catheter and the tail portion defining the inset within the bulbous portion, wherein the implant has a height that is approximately the same in the intermediate stage and in the final stage.

2. The system of claim 1, wherein the bulbous portion has a teardrop shape in the intermediate stage.

3. The system of claim 1, wherein the bulbous portion has a mushroom shape in the intermediate stage.

4. The system of claim 1, wherein the inset is configured to be recapturable in clinical use.

5. The system of claim 1, wherein the inset is configured so that it is not recapturable in clinical use.

6. The system of claim 5, wherein the inset is substantially spherical.

7. The system of claim 5, wherein the inset has an opposing cone shape.

8. The system of claim 5, wherein the inset includes an inverted hub.

9. The system of claim 5, wherein the inset includes no hub.

10. The system of claim 9, wherein the inset is adapted to expand from a compressed conical shape.

11. The system of claim 10, wherein the inset is adapted to expand into the bulbous portion.

Referenced Cited
U.S. Patent Documents
3108593 October 1963 Glassman
4425908 January 17, 1984 Simon
4619246 October 28, 1986 Molgaard-Nielsen et al.
4655771 April 7, 1987 Wallsten
4768507 September 6, 1988 Fischell et al.
4921484 May 1, 1990 Hillstead
4998539 March 12, 1991 Delsante
5026377 June 25, 1991 Burton et al.
5061275 October 29, 1991 Wallsten et al.
5064435 November 12, 1991 Porter
5104404 April 14, 1992 Wolff
5122136 June 16, 1992 Guglielmi et al.
5158548 October 27, 1992 Lau et al.
5222971 June 29, 1993 Willard et al.
5250071 October 5, 1993 Palermo
5334210 August 2, 1994 Gianturco
5378239 January 3, 1995 Termin et al.
5405379 April 11, 1995 Lane
5425984 June 20, 1995 Kennedy et al.
5484444 January 16, 1996 Braunschweiler et al.
5499981 March 19, 1996 Kordis
5527338 June 18, 1996 Purdy
5545208 August 13, 1996 Wolff et al.
5545209 August 13, 1996 Roberts et al.
5549635 August 27, 1996 Solar
5624461 April 29, 1997 Mariant
5634942 June 3, 1997 Chevillon et al.
5645558 July 8, 1997 Horton
5662703 September 2, 1997 Yurek et al.
5690671 November 25, 1997 McGurk et al.
5702419 December 30, 1997 Berry et al.
5713907 February 3, 1998 Hogendijk et al.
5725552 March 10, 1998 Kotula et al.
5728906 March 17, 1998 Eguchi et al.
5733294 March 31, 1998 Forber et al.
5741333 April 21, 1998 Frid
5749891 May 12, 1998 Ken et al.
5749919 May 12, 1998 Blanc
5749920 May 12, 1998 Quiachon et al.
5766151 June 16, 1998 Valley et al.
5814062 September 29, 1998 Sepetka et al.
5830230 November 3, 1998 Berryman et al.
5846261 December 8, 1998 Kotula et al.
5853422 December 29, 1998 Huebsch et al.
5855578 January 5, 1999 Guglielmi et al.
5879366 March 9, 1999 Shaw et al.
5908435 June 1, 1999 Samuels
5911731 June 15, 1999 Pham et al.
5916235 June 29, 1999 Guglielmi
5925060 July 20, 1999 Forber
5928228 July 27, 1999 Kordis et al.
5928260 July 27, 1999 Chin et al.
5935148 August 10, 1999 Villar et al.
5935362 August 10, 1999 Petrick
5941249 August 24, 1999 Maynard
5944738 August 31, 1999 Amplatz et al.
5951599 September 14, 1999 McCrory
5957948 September 28, 1999 Mariant
5976162 November 2, 1999 Doan et al.
5980554 November 9, 1999 Lenker et al.
6001092 December 14, 1999 Mirigian et al.
6010517 January 4, 2000 Baccaro
6024756 February 15, 2000 Huebsch et al.
6033423 March 7, 2000 Ken et al.
6036720 March 14, 2000 Abrams et al.
6059813 May 9, 2000 Vrba et al.
6063070 May 16, 2000 Eder
6063104 May 16, 2000 Villar et al.
6086577 July 11, 2000 Ken et al.
6093199 July 25, 2000 Brown et al.
6096034 August 1, 2000 Kupiecki et al.
6096073 August 1, 2000 Webster et al.
6099526 August 8, 2000 Whayne et al.
6106530 August 22, 2000 Harada
6110191 August 29, 2000 Dehdashtian et al.
6123715 September 26, 2000 Amplatz
6139564 October 31, 2000 Teoh
6152144 November 28, 2000 Lesh et al.
6168592 January 2, 2001 Kupiecki et al.
6168615 January 2, 2001 Ken et al.
6168618 January 2, 2001 Frantzen
6168622 January 2, 2001 Mazzocchi
6183495 February 6, 2001 Lenker et al.
6190402 February 20, 2001 Horton et al.
6193708 February 27, 2001 Ken et al.
6221086 April 24, 2001 Forber
6261305 July 17, 2001 Marotta et al.
6280412 August 28, 2001 Pederson, Jr. et al.
6306141 October 23, 2001 Jervis
6309367 October 30, 2001 Boock
6322576 November 27, 2001 Wallace et al.
6325820 December 4, 2001 Khosravi et al.
6331184 December 18, 2001 Abrams
6332576 December 25, 2001 Colley et al.
6342068 January 29, 2002 Thompson
6344041 February 5, 2002 Kupiecki et al.
6344048 February 5, 2002 Chin et al.
6346117 February 12, 2002 Greenhalgh
6350270 February 26, 2002 Roue
6361558 March 26, 2002 Hieshima et al.
6368339 April 9, 2002 Amplatz
6375668 April 23, 2002 Gifford et al.
6379372 April 30, 2002 Dehdashtian et al.
6383174 May 7, 2002 Eder
6391037 May 21, 2002 Greenhalgh
6409750 June 25, 2002 Hyodoh et al.
6428558 August 6, 2002 Jones et al.
6443972 September 3, 2002 Bosma et al.
6447531 September 10, 2002 Amplatz
6454780 September 24, 2002 Wallace
6506204 January 14, 2003 Mazzocchi
6511468 January 28, 2003 Cragg et al.
6530934 March 11, 2003 Jacobsen
6544278 April 8, 2003 Vrba et al.
6547804 April 15, 2003 Porter et al.
6551303 April 22, 2003 Van Tassel et al.
6569179 May 27, 2003 Teoh et al.
6579302 June 17, 2003 Duerig et al.
6579303 June 17, 2003 Amplatz
6585748 July 1, 2003 Jeffree
6585756 July 1, 2003 Strecker
6589256 July 8, 2003 Forber
6589265 July 8, 2003 Palmer et al.
6592605 July 15, 2003 Lenker et al.
6599308 July 29, 2003 Amplatz
6605102 August 12, 2003 Mazzocchi et al.
6605111 August 12, 2003 Bose et al.
6607551 August 19, 2003 Sullivan et al.
6613074 September 2, 2003 Mitelberg et al.
6626939 September 30, 2003 Burnside et al.
6632241 October 14, 2003 Hancock et al.
6635068 October 21, 2003 Dubrul et al.
6635069 October 21, 2003 Teoh et al.
6652555 November 25, 2003 VanTassel et al.
6652556 November 25, 2003 VanTassel et al.
6666882 December 23, 2003 Bose et al.
6666883 December 23, 2003 Seguin et al.
6669717 December 30, 2003 Marotta et al.
6669721 December 30, 2003 Bose et al.
6676696 January 13, 2004 Marotta et al.
6682505 January 27, 2004 Bates et al.
6682546 January 27, 2004 Amplatz
6689150 February 10, 2004 VanTassel et al.
6689486 February 10, 2004 Ho et al.
6695876 February 24, 2004 Marotta et al.
6698877 March 2, 2004 Urlaub et al.
6699274 March 2, 2004 Stinson
6709465 March 23, 2004 Mitchell et al.
6712835 March 30, 2004 Mazzocchi et al.
6723112 April 20, 2004 Ho et al.
6723116 April 20, 2004 Taheri
6730108 May 4, 2004 Van Tassel et al.
6746468 June 8, 2004 Sepetka et al.
6746890 June 8, 2004 Gupta et al.
6780196 August 24, 2004 Chin et al.
6792979 September 21, 2004 Konya et al.
6797083 September 28, 2004 Peterson
6802851 October 12, 2004 Jones et al.
RE38653 November 16, 2004 Igaki et al.
6811560 November 2, 2004 Jones et al.
6855153 February 15, 2005 Saadat
6855154 February 15, 2005 Abdel-Gawwad
RE38711 March 15, 2005 Igaki et al.
6860893 March 1, 2005 Wallace et al.
6936055 August 30, 2005 Ken et al.
6949103 September 27, 2005 Mazzocchi et al.
6949113 September 27, 2005 Van Tassel et al.
6953472 October 11, 2005 Palmer et al.
6979341 December 27, 2005 Scribner et al.
6989019 January 24, 2006 Mazzocchi et al.
6994092 February 7, 2006 van der Burg et al.
6994717 February 7, 2006 Konya et al.
7011671 March 14, 2006 Welch
7018401 March 28, 2006 Hyodoh et al.
7029487 April 18, 2006 Greene, Jr. et al.
7033375 April 25, 2006 Mazzocchi et al.
7048752 May 23, 2006 Mazzocchi et al.
7063679 June 20, 2006 Maguire et al.
7070607 July 4, 2006 Murayama et al.
7070609 July 4, 2006 West
7083632 August 1, 2006 Avellanet et al.
7128073 October 31, 2006 van der Burg et al.
7128736 October 31, 2006 Abrams et al.
7169177 January 30, 2007 Obara
7195636 March 27, 2007 Avellanet et al.
7211109 May 1, 2007 Thompson
7229461 June 12, 2007 Chin et al.
7232461 June 19, 2007 Ramer
7244267 July 17, 2007 Huter et al.
7261720 August 28, 2007 Stevens et al.
7303571 December 4, 2007 Makower et al.
7306622 December 11, 2007 Jones et al.
7331980 February 19, 2008 Dubrul et al.
7367985 May 6, 2008 Mazzocchi et al.
7367986 May 6, 2008 Mazzocchi et al.
7371250 May 13, 2008 Mazzocchi et al.
7393358 July 1, 2008 Malewicz
7404820 July 29, 2008 Mazzocchi et al.
7410482 August 12, 2008 Murphy et al.
7410492 August 12, 2008 Mazzocchi et al.
7413622 August 19, 2008 Peterson
7419503 September 2, 2008 Pulnev et al.
7442200 October 28, 2008 Mazzocchi et al.
7485088 February 3, 2009 Murphy et al.
7556635 July 7, 2009 Mazzocchi et al.
7566338 July 28, 2009 Mazzocchi et al.
7569066 August 4, 2009 Gerberding et al.
7572273 August 11, 2009 Mazzocchi et al.
7572288 August 11, 2009 Cox
7575590 August 18, 2009 Watson
7597704 October 6, 2009 Frazier et al.
7608088 October 27, 2009 Jones et al.
7621928 November 24, 2009 Thramann et al.
7632296 December 15, 2009 Malewicz
7670355 March 2, 2010 Mazzocchi et al.
7670356 March 2, 2010 Mazzocchi et al.
7678130 March 16, 2010 Mazzocchi et al.
7682390 March 23, 2010 Seguin
7691124 April 6, 2010 Balgobin
7695488 April 13, 2010 Berenstein et al.
7699056 April 20, 2010 Tran et al.
7727189 June 1, 2010 VanTassel et al.
7744583 June 29, 2010 Seifert et al.
7744652 June 29, 2010 Morsi
7763011 July 27, 2010 Ortiz et al.
7828815 November 9, 2010 Mazzocchi et al.
7828816 November 9, 2010 Mazzocchi et al.
7906066 March 15, 2011 Wilson et al.
7922732 April 12, 2011 Mazzocchi et al.
7955343 June 7, 2011 Makower et al.
7972359 July 5, 2011 Kreidler
7993364 August 9, 2011 Morsi
RE42758 September 27, 2011 Ken et al.
8016869 September 13, 2011 Nikolchev
8016872 September 13, 2011 Parker
8062379 November 22, 2011 Morsi
8075585 December 13, 2011 Lee et al.
8142456 March 27, 2012 Rosqueta et al.
8202280 June 19, 2012 Richter
8221445 July 17, 2012 van Tassel et al.
8261648 September 11, 2012 Marchand et al.
8298257 October 30, 2012 Sepetka et al.
8430012 April 30, 2013 Marchand et al.
8454681 June 4, 2013 Holman et al.
20010000797 May 3, 2001 Mazzocchi
20010007082 July 5, 2001 Dusbabek et al.
20010012949 August 9, 2001 Forber
20010051822 December 13, 2001 Stack et al.
20020013599 January 31, 2002 Limon et al.
20020013618 January 31, 2002 Marotta et al.
20020042628 April 11, 2002 Chin et al.
20020062091 May 23, 2002 Jacobsen et al.
20020111647 August 15, 2002 Khairkhahan et al.
20020165572 November 7, 2002 Saadat
20020169473 November 14, 2002 Sepetka et al.
20030004538 January 2, 2003 Secrest et al.
20030028209 February 6, 2003 Teoh et al.
20030057156 March 27, 2003 Peterson et al.
20030171739 September 11, 2003 Murphy et al.
20030171770 September 11, 2003 Kusleika et al.
20030176884 September 18, 2003 Berrada et al.
20030195553 October 16, 2003 Wallace et al.
20030199913 October 23, 2003 Dubrul et al.
20030199919 October 23, 2003 Palmer et al.
20040015224 January 22, 2004 Armstrong et al.
20040034386 February 19, 2004 Fulton et al.
20040044391 March 4, 2004 Porter
20040098027 May 20, 2004 Teoh et al.
20040098030 May 20, 2004 Makower et al.
20040106945 June 3, 2004 Thramann et al.
20040106977 June 3, 2004 Sullivan et al.
20040111112 June 10, 2004 Hoffmann
20040122467 June 24, 2004 VanTassel et al.
20040122468 June 24, 2004 Yodfat et al.
20040143239 July 22, 2004 Zhou et al.
20040143286 July 22, 2004 Johnson et al.
20040153119 August 5, 2004 Kusleika et al.
20040162606 August 19, 2004 Thompson
20040172056 September 2, 2004 Guterman et al.
20040172121 September 2, 2004 Eidenschink et al.
20040181253 September 16, 2004 Sepetka et al.
20040186562 September 23, 2004 Cox
20040193206 September 30, 2004 Gerberding et al.
20040215229 October 28, 2004 Coyle
20040215332 October 28, 2004 Frid
20040249408 December 9, 2004 Murphy et al.
20040267346 December 30, 2004 Shelso
20050010281 January 13, 2005 Yodfat et al.
20050021077 January 27, 2005 Chin et al.
20050033408 February 10, 2005 Jones et al.
20050033409 February 10, 2005 Burke et al.
20050043759 February 24, 2005 Chanduszko
20050060017 March 17, 2005 Fischell et al.
20050096728 May 5, 2005 Ramer
20050096732 May 5, 2005 Marotta et al.
20050107823 May 19, 2005 Leone et al.
20050131443 June 16, 2005 Abdel-Gawwad
20050222605 October 6, 2005 Greenhalgh
20050228434 October 13, 2005 Amplatz et al.
20050267568 December 1, 2005 Berez et al.
20050273135 December 8, 2005 Chanduszko et al.
20050288763 December 29, 2005 Andreas et al.
20060052816 March 9, 2006 Bates et al.
20060064151 March 23, 2006 Guterman et al.
20060074475 April 6, 2006 Gumm
20060106421 May 18, 2006 Teoh
20060116713 June 1, 2006 Sepetka et al.
20060116714 June 1, 2006 Sepetka et al.
20060155323 July 13, 2006 Porter et al.
20060167494 July 27, 2006 Suddaby
20060190070 August 24, 2006 Dieck et al.
20060190076 August 24, 2006 Taheri
20060200221 September 7, 2006 Malewicz
20060206199 September 14, 2006 Churchwell et al.
20060206200 September 14, 2006 Garcia et al.
20060217799 September 28, 2006 Mailander et al.
20060229700 October 12, 2006 Acosta et al.
20060235464 October 19, 2006 Avellanet et al.
20060235501 October 19, 2006 Igaki
20060241690 October 26, 2006 Amplatz et al.
20060247680 November 2, 2006 Amplatz et al.
20060264905 November 23, 2006 Eskridge et al.
20060264907 November 23, 2006 Eskridge et al.
20060271149 November 30, 2006 Berez et al.
20060271153 November 30, 2006 Garcia et al.
20060276827 December 7, 2006 Mitelberg et al.
20060282152 December 14, 2006 Beyerlein et al.
20060292206 December 28, 2006 Kim et al.
20060293744 December 28, 2006 Peckham et al.
20070005125 January 4, 2007 Berenstein et al.
20070016243 January 18, 2007 Ramaiah et al.
20070021816 January 25, 2007 Rudin
20070050017 March 1, 2007 Sims et al.
20070088387 April 19, 2007 Eskridge et al.
20070093889 April 26, 2007 Wu et al.
20070100415 May 3, 2007 Licata et al.
20070106311 May 10, 2007 Wallace et al.
20070135826 June 14, 2007 Zaver et al.
20070150045 June 28, 2007 Ferrera
20070162104 July 12, 2007 Frid
20070173928 July 26, 2007 Morsi
20070191884 August 16, 2007 Eskridge et al.
20070191924 August 16, 2007 Rudakov
20070198075 August 23, 2007 Levy
20070203567 August 30, 2007 Levy
20070219619 September 20, 2007 Dieck et al.
20070221230 September 27, 2007 Thompson et al.
20070225760 September 27, 2007 Moszner et al.
20070225794 September 27, 2007 Thramann et al.
20070233224 October 4, 2007 Leynov et al.
20070233244 October 4, 2007 Lopez et al.
20070239261 October 11, 2007 Bose et al.
20070265656 November 15, 2007 Amplatz et al.
20070270902 November 22, 2007 Slazas et al.
20070288083 December 13, 2007 Hines
20070293935 December 20, 2007 Olsen et al.
20080009934 January 10, 2008 Schneider et al.
20080021535 January 24, 2008 Leopold et al.
20080039933 February 14, 2008 Yodfat et al.
20080045996 February 21, 2008 Makower et al.
20080045997 February 21, 2008 Balgobin et al.
20080051705 February 28, 2008 Von Oepen et al.
20080058856 March 6, 2008 Ramaiah et al.
20080065141 March 13, 2008 Holman et al.
20080065145 March 13, 2008 Carpenter
20080097495 April 24, 2008 Feller, III et al.
20080109063 May 8, 2008 Hancock et al.
20080114391 May 15, 2008 Dieck et al.
20080114436 May 15, 2008 Dieck et al.
20080114439 May 15, 2008 Ramaiah et al.
20080119886 May 22, 2008 Greenhalgh et al.
20080125806 May 29, 2008 Mazzocchi et al.
20080125848 May 29, 2008 Kusleika et al.
20080132989 June 5, 2008 Snow et al.
20080140177 June 12, 2008 Hines
20080154286 June 26, 2008 Abbott et al.
20080195139 August 14, 2008 Donald et al.
20080219533 September 11, 2008 Grigorescu
20080221600 September 11, 2008 Dieck et al.
20080243226 October 2, 2008 Fernandez et al.
20080249562 October 9, 2008 Cahill
20080262598 October 23, 2008 Elmaleh
20080281350 November 13, 2008 Sepetka et al.
20080319533 December 25, 2008 Lehe
20090025820 January 29, 2009 Adams
20090069806 March 12, 2009 De La Mora Levy et al.
20090082803 March 26, 2009 Adams et al.
20090099647 April 16, 2009 Glimsdale et al.
20090112251 April 30, 2009 Qian et al.
20090118811 May 7, 2009 Moloney
20090125094 May 14, 2009 Rust
20090143849 June 4, 2009 Ozawa et al.
20090143851 June 4, 2009 Paul, Jr.
20090198315 August 6, 2009 Boudjemline
20090204145 August 13, 2009 Matthews
20090210047 August 20, 2009 Amplatz et al.
20090216307 August 27, 2009 Kaufmann et al.
20090228029 September 10, 2009 Lee
20090228093 September 10, 2009 Taylor et al.
20090259202 October 15, 2009 Leeflang et al.
20090264914 October 22, 2009 Riina et al.
20090275974 November 5, 2009 Marchand et al.
20090287291 November 19, 2009 Becking et al.
20090287294 November 19, 2009 Rosqueta et al.
20090287297 November 19, 2009 Cox
20090318941 December 24, 2009 Sepetka et al.
20090318948 December 24, 2009 Linder
20100004726 January 7, 2010 Hancock et al.
20100004761 January 7, 2010 Flanders et al.
20100023048 January 28, 2010 Mach
20100023105 January 28, 2010 Levy et al.
20100030220 February 4, 2010 Truckai et al.
20100036390 February 11, 2010 Gumm
20100042133 February 18, 2010 Ramzipoor et al.
20100069948 March 18, 2010 Veznedaroglu et al.
20100087908 April 8, 2010 Hilaire et al.
20100094335 April 15, 2010 Gerberding et al.
20100131002 May 27, 2010 Connor et al.
20100152767 June 17, 2010 Greenhalgh et al.
20100185271 July 22, 2010 Zhang
20100222802 September 2, 2010 Gillespie, Jr. et al.
20100249894 September 30, 2010 Oba et al.
20100268260 October 21, 2010 Riina et al.
20100274276 October 28, 2010 Chow et al.
20100312270 December 9, 2010 McGuckin, Jr. et al.
20100331948 December 30, 2010 Turovskiy et al.
20110022149 January 27, 2011 Cox et al.
20110054519 March 3, 2011 Neuss
20110082493 April 7, 2011 Samson et al.
20110106234 May 5, 2011 Grandt
20110144669 June 16, 2011 Becking et al.
20110152993 June 23, 2011 Marchand et al.
20110184452 July 28, 2011 Huynh et al.
20110184453 July 28, 2011 Levy et al.
20110196415 August 11, 2011 Ujiie et al.
20110202085 August 18, 2011 Loganathan et al.
20110208227 August 25, 2011 Becking
20110245862 October 6, 2011 Dieck et al.
20110265943 November 3, 2011 Rosqueta et al.
20110276120 November 10, 2011 Gilson et al.
20110313447 December 22, 2011 Strauss et al.
20110319926 December 29, 2011 Becking et al.
20120041470 February 16, 2012 Shrivastava et al.
20120065720 March 15, 2012 Strauss et al.
20120101561 April 26, 2012 Porter
20120143237 June 7, 2012 Cam et al.
20120143317 June 7, 2012 Cam et al.
20120165803 June 28, 2012 Bencini et al.
20120165919 June 28, 2012 Cox et al.
20120197283 August 2, 2012 Marchand et al.
20120226343 September 6, 2012 Vo et al.
20120245674 September 27, 2012 Molaei et al.
20120245675 September 27, 2012 Molaei et al.
20120283768 November 8, 2012 Cox et al.
20120316598 December 13, 2012 Becking et al.
20120330341 December 27, 2012 Becking et al.
20120330347 December 27, 2012 Becking et al.
20130018451 January 17, 2013 Grabowski et al.
20130066357 March 14, 2013 Aboytes et al.
20130066360 March 14, 2013 Becking et al.
20130085522 April 4, 2013 Becking et al.
20130092013 April 18, 2013 Thompson et al.
20130123830 May 16, 2013 Becking et al.
20130211495 August 15, 2013 Halden et al.
20130233160 September 12, 2013 Marchand et al.
20130239790 September 19, 2013 Thompson et al.
20130245667 September 19, 2013 Marchand et al.
20130245670 September 19, 2013 Fan
20130268053 October 10, 2013 Molaei
20130274862 October 17, 2013 Cox et al.
20130274863 October 17, 2013 Cox et al.
20130274866 October 17, 2013 Cox et al.
20130274868 October 17, 2013 Cox et al.
20130304179 November 14, 2013 Bialas et al.
20130345739 December 26, 2013 Brady et al.
20140005713 January 2, 2014 Bowman
20140128905 May 8, 2014 Molaei
Foreign Patent Documents
2607529 April 2008 CA
101472537 July 2009 CN
1283434 November 1968 DE
102008028308 April 2009 DE
102010050569 May 2012 DE
102011011510 August 2012 DE
743047 November 1996 EP
775470 May 1997 EP
855170 July 1998 EP
1621148 February 2006 EP
1637176 March 2006 EP
1752112 February 2007 EP
1942972 July 2008 EP
1872742 May 2009 EP
2279023 February 2011 EP
2363075 September 2011 EP
2496299 September 2012 EP
2675402 December 2013 EP
2556210 April 1988 FR
2890306 March 2007 FR
11-506686 June 1999 JP
2003-520103 July 2003 JP
2003-524434 August 2003 JP
2004-049585 February 2004 JP
2005-522266 July 2005 JP
2006-506201 February 2006 JP
2008-541832 November 2008 JP
4673987 April 2011 JP
WO-88/00813 February 1988 WO
WO-96/01591 January 1996 WO
WO-97/26939 July 1997 WO
WO-99/03404 January 1999 WO
WO-99/05977 February 1999 WO
WO-99/08607 February 1999 WO
WO-99/08743 February 1999 WO
WO-99/40873 August 1999 WO
WO-99/62432 December 1999 WO
WO-00/57815 October 2000 WO
WO-01/93782 December 2001 WO
WO-02/000139 January 2002 WO
WO-02/071977 September 2002 WO
WO-03/037191 May 2003 WO
WO-2005/117718 December 2005 WO
WO-2006/026744 March 2006 WO
WO-2006/034166 March 2006 WO
WO-2006/052322 May 2006 WO
WO-2006/091891 August 2006 WO
WO-2006/119422 November 2006 WO
WO-2007/047851 April 2007 WO
WO-2007/076480 July 2007 WO
WO-2007/095031 August 2007 WO
WO-2007/121405 October 2007 WO
WO-2008/022327 February 2008 WO
WO-2008/109228 September 2008 WO
WO-2008/151204 December 2008 WO
WO-2008/157507 December 2008 WO
WO-2009/076515 June 2009 WO
WO-2009/132045 October 2009 WO
WO-2009/134337 November 2009 WO
WO-2009/135166 November 2009 WO
WO-2010/028314 March 2010 WO
WO-2010/030991 March 2010 WO
WO-2010/147808 December 2010 WO
WO-2011/057002 May 2011 WO
WO-2011/057277 May 2011 WO
WO-2011/130081 October 2011 WO
WO-2011/153304 December 2011 WO
WO-2012/068175 May 2012 WO
WO-2012/112749 August 2012 WO
WO-2012/166804 December 2012 WO
Other references
  • Hill, et al., “Initial Results of the AMPLATZER Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004.
  • Ronnen, “AMPLATZER Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007.
  • Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040.
  • U.S. Appl. No. 13/826,298, filed Mar. 14, 2013.
  • U.S. Appl. No. 13/795,556, filed Mar. 12, 2013.
  • U.S. Appl. No. 13/669,652, filed Nov. 6, 2012.
Patent History
Patent number: 9393022
Type: Grant
Filed: Aug 8, 2013
Date of Patent: Jul 19, 2016
Patent Publication Number: 20140172001
Assignee: Covidien LP (Mansfield, MA)
Inventors: Frank P. Becking (Santa Clara, CA), Karl S. Halden (San Carlos, CA), Martin S. Dieck (Campbell, CA), Nicholas C. Debeer (Montara, CA), Teresa Ruvalcaba (Palo Alto, CA), Andre-Jean Lundkvist (Palo Alto, CA)
Primary Examiner: Todd J Scherbel
Application Number: 13/962,267
Classifications
Current U.S. Class: Occluding Clip, Clamp, Or Band (606/157)
International Classification: A61B 17/12 (20060101); A61B 17/00 (20060101);